Dangal actor Suhani Bhatnagar dies of rare disease called Dermatomyositis

Dermatomyositis, a rare and challenging autoimmune disorder, recently claimed the life of Suhani Bhatnagar, a young and talented actress best known for her portrayal of young Babita Phogat in Aamir Khan’s acclaimed wrestling film, “Dangal”. At just 19 years old, Suhani’s untimely passing in Delhi has cast a spotlight on this uncommon disease, following a brief battle that began with symptoms emerging just two months ago and a diagnosis confirmed merely ten days before her tragic demise.

This condition is marked by the immune system erroneously attacking the body’s own tissues, leading to inflammation and consequent damage, predominantly affecting the skin and muscles. Individuals with dermatomyositis experience a variety of symptoms, most notably a distinctive skin rash that manifests as reddish or purplish discoloration on the face, neck, shoulders, chest, and sometimes extends to the elbows, knees, and knuckles. The disease also causes muscle weakness and fatigue, severely impacting the ability to perform daily tasks and activities.

While the exact cause of dermatomyositis remains elusive, it is believed to result from a mix of genetic susceptibilities, environmental factors, and immune system irregularities, with certain medications or infections potentially triggering its onset.

Treatment strategies for dermatomyositis focus on controlling the immune system’s overactivity through medications and employing physical therapy to maintain muscle strength and flexibility. Proper management enables many individuals diagnosed with this condition to lead active and fulfilling lives, despite the need for ongoing care and vigilance to prevent further complications.

Powered by WPeMatico

Parliamentary Committee recommends multiple measures to make medical education more affordable

Taking note of the problems faced by medical aspirants due to the huge cost of medical education in private medical colleges in India, a Parliamentary Committee on Health has recommended multiple measures to the Government to deal with the issue.

The panel has opined that running medical colleges and hospitals on a PPP model and giving tax benefits to the company/group could also help make medical education more affordable.

Apart from these, the panel has recommended the Ministry formulate a comprehensive framework to address the bureaucratic hurdles and effectively implement the partnership of the private medical colleges with the district hospitals.

For the full story, check out the link given below:

How Can Medical Education Be Made More Affordable? Here Is What Parliamentary Committee Said

Powered by WPeMatico

Remission of Cushing’s disease associated with higher risk of developing autoimmune disease

A study of more than 250 persons undergoing surgical therapy for Cushing’s disease (CD) or nonfunctioning pituitary adenomas (NFPAs) found that patients who achieved remission of CD were more likely than those with surgically treated NFPAs to develop new-onset autoimmune disease within three years after remission. The study is published in Annals of Internal Medicine.

Powered by WPeMatico

Health care inequities behind shorter life spans for Inuit from Nunavik, Quebec, with lung cancer

People living in the Inuit region of Nunavik in northern Quebec die earlier after a diagnosis of lung cancer than Montreal residents receiving treatment at the same cancer center, according to new research published in theCanadian Medical Association Journal.

Powered by WPeMatico

Anorexia nervosa can be life-threatening in males

Anorexia nervosa affects males as well as females, and affected males have a sixfold higher mortality rate than males in the general population. A new article published in the Canadian Medical Association Journal aims to raise awareness of this life-threatening eating disorder.

Powered by WPeMatico

Analysis identifies more than 275 million previously unreported genetic variations

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences.

Powered by WPeMatico

Researchers combine modern equipment for increased precision in body composition analysis

Locating specific, localized distributions of fat and muscle in body composition is intuitively and imprecisely implied by body shape. Now, a team of researchers has discovered that the unique combination of modern deep learning models, specified equipment and three-dimensional body scans has given a quantitative validation on medical imaging that was previously only qualitative.

Powered by WPeMatico

Debunking myths related to diabetes, sugar control & associated complications – Dr Suneel Bharadwaj

Lower HbA1c levels are associated with reduced risks of heart disease, kidney problems, nerve damage, and eye issues. Achieving this target helps improve overall quality of life and ensures better control over diabetes-related complications. However, individualized treatment goals may vary, and it’s essential to consult a healthcare professional to determine the most appropriate target for each person with diabetes.

Contrary to the myth that diabetes is solely a sugar control issue, it involves a range of complications. Prolonged high blood sugar levels can lead to serious issues such as heart disease, kidney problems, nerve damage, vision impairment, and even amputations. It affects the entire body, highlighting the importance of comprehensive diabetes management, including lifestyle changes, medication, and regular monitoring, to prevent these complications and maintain overall health.

In this video, Dr Suneel Bhardwaj, General Physician from Delhi, discusses why it is important for people with diabetes to maintain HbA1C below 7%. He dispels the myth that diabetes is merely a sugar control issue.

Powered by WPeMatico

Pfizer gets EU nod for ulcerative colitis drug Velsipity

Pfizer’s drug to treat patients with an inflammatory bowel disease called ulcerative colitis has been approved by the European Commission, the company said on Monday.

The approval for Velsipity follows backing from the European Medicines Agency’s panel of experts in December.
The drug was approved for use in patients aged 16 or older and who did not show adequate response or were intolerant to previous treatment, Pfizer said.
The approval, applicable in all 27 countries of the European Union, is based on studies from two late-stage trials that showed the drug was effective and safe in eligible patients.
Pfizer said Velsipity will be available in each of the member countries after the national processes are complete, including applications for reimbursement for the drug.
About 2.6 million people in Europe are living with ulcerative colitis, Pfizer says.
Velsipity, which was approved in the United States in October, belongs to a class of drugs used to regulate the body’s immune response and is expected to compete with Bristol Myers Squibb’s Zeposia.
Pfizer has also sought regulatory approvals for the drug in Australia, India and the UK, among others.
Leerink Partners in October estimated the drug’s 2030 sales at $2.2 billion.
Read also: Pfizer, UT Southwestern collaborate to develop improved RNA Delivery Technologies

Powered by WPeMatico

ADA releases new guideline for pharmacologic management of acute dental pain in adults, adolescents and older adults

USA: A recent article published in The Journal of the American Dental Association has reported key recommendations and good practice statements for the pharmacologic management of acute dental pain: postoperative pain after simple and surgical tooth extraction(s) in adolescents, adults, and older adults.

The document stated, that there is a beneficial net balance favoring the use of nonopioid medications compared with opioid medications. In particular, nonsteroidal anti-inflammatory drugs alone or in combination with acetaminophen likely provide superior pain relief with a more favourable safety profile than opioids.

The evidence-based recommendations were formulated by a panel convened by the American Dental Association Science and Research Institute, the University of Pennsylvania, and the University of Pittsburgh. For recommendations formulation, the panel used the Grading of Recommendations, Assessment, Development and Evaluation approach to assess the certainty of the evidence and the Grading of Recommendations, Assessment, Development and Evaluation Evidence-to-Decision Framework.

Nonopioid medications are first-line therapy for managing acute dental pain after tooth extraction(s) and the temporary management of toothache.

“The use of opioids should be reserved for clinical situations when the first-line therapy is insufficient to reduce pain or there is a contraindication of nonsteroidal anti-inflammatory drugs,” the panel stated.

“Clinicians should avoid the routine use of just-in-case prescribing of opioids and should exert extreme caution when prescribing opioids to adolescents and young adults.”

The key recommendations are described below:

  • For the management of acute postoperative dental pain in adolescents, adults, and older adults undergoing surgical tooth extraction(s), the panel recommends the postprocedural use of nonopioid analgesics as first-line therapy instead of opioid analgesics.
  • For surgical tooth extraction(s), the panel suggests initiating the postoperative pain management using a nonsteroidal anti-inflammatory drug (NSAID) alone (eg, 400 mg of ibuprofen or 440 mg of naproxen sodium) or in combination with acetaminophen (eg, 500 mg).
  • In the rare instances when postprocedural (ie, surgical tooth extraction) pain control using NSAIDs alone is inadequate, the panel suggests the addition to the previous first-line therapy prescription (ie, NSAID) of 325 mg of acetaminophen plus a combination of 325 mg of acetaminophen with an opioid (eg, 5-7.5 mg of hydrocodone or 5 mg of oxycodone) at the lowest effective dose, fewest tablets, and the shortest duration, which rarely exceeds 3 days.
  • In the rare instances when postprocedural (ie, surgical tooth extraction) pain control using NSAIDs in combination with acetaminophen (eg, 500 mg) is inadequate, the panel suggests replacing the initial first-line therapy prescription with an NSAID (eg, 400 mg of ibuprofen or 440 mg of naproxen sodium) and 325 mg of acetaminophen plus a combination of 325 mg of acetaminophen with an opioid (eg, 5-7.5 mg of hydrocodone or 5 mg of oxycodone). The opioid prescription should consider the lowest effective dose, the fewest tablets, and the shortest duration, which rarely exceeds 3 days.
  • When NSAIDs are contraindicated, the panel suggests the postprocedural use of acetaminophen alone at the full therapeutic dose (eg, 1,000 mg) or 325 mg of acetaminophen plus a combination of 325 mg of acetaminophen with an opioid (eg, 5-7.5 mg of hydrocodone or 5 mg of oxycodone) at the lowest effective dose, fewest tablets, and the shortest duration, which rarely exceeds 3 days.
  • For the management of acute postoperative dental pain in adolescents, adults, and older adults undergoing surgical tooth extraction(s), the panel suggests against adding oral, submucosal, or intramuscular corticosteroids to standard analgesic therapy (conditional, very low certainty).
  • For the management of acute postoperative dental pain in adolescents, adults, and older adults undergoing simple tooth extraction(s), the panel recommends the postprocedural use of nonopioid analgesics only and recommends against the use of opioid analgesics (conditional, low certainty).
  • For simple tooth extraction, the panel suggests initiating the pain management using an NSAID alone (eg, 400 mg of ibuprofen or 440 mg of naproxen sodium) or in combination with acetaminophen (eg, 500 mg).
  • When NSAIDs are contraindicated, the panel suggests the postprocedural use of acetaminophen alone at a full therapeutic dose (eg, 1,000 mg).
  • For the management of acute postoperative dental pain in adolescents, adults, and older adults undergoing simple and surgical tooth extraction(s), the panel suggests the postprocedural use (ie, before patient discharge) of 0.5% bupivacaine plus 1:200,000 epinephrine by block or infiltration injection or 4% articaine plus 1:100,000/1:200,000 epinephrine by infiltration injection instead of 2% lidocaine plus 1:100,000 epinephrine or 3% mepivacaine.

Good Practice Statements

  • The panel advises clinicians to counsel patients that they should expect some pain and the analgesics should make their pain manageable. The panel also recommends discussing with the patient their experience, preferences, and values regarding managing acute dental pain before prescribing.
  • The panel recommends clinicians thoroughly review the patient’s medical and social history (including illicit and recreational drug use), medications, and supplements to avoid overdose and adverse drug-drug interactions.
  • To minimize adverse effects, analgesic prescriptions should follow the principle of minimum effective dosage to achieve pain relief and avoid the routine use of delayed (ie, just-in-case prescription for breakthrough pain) opioid prescriptions.
  • If an NSAID alone or in combination with acetaminophen fails to provide adequate pain relief, and if opioids are prescribed, counsel patients regarding appropriate storage and disposal.
  • The panel recommends clinicians review the state’s prescription drug monitoring program when available to determine the prescribing of other controlled substances (eg, opioids and benzodiazepines). If the patient with acute dental pain is already receiving opioids to manage chronic pain (ie, long-term use of opioids), clinicians should prioritize the use of nonopioid analgesics (ie, first-line analgesic therapy).
  • Special care should be taken when prescribing opioids to a patient with a substance use disorder, including communication with the patient’s other healthcare providers.

Reference:

Carrasco-Labra, A., Polk, D. E., Urquhart, O., Aghaloo, T., Claytor, J. W., Dhar, V., Dionne, R. A., Espinoza, L., Gordon, S. M., Hersh, E. V., Law, A. S., Li, B. S. K., Schwartz, P. J., Suda, K. J., Turturro, M. A., Wright, M. L., Dawson, T., Miroshnychenko, A., Pahlke, S., . . . Moore, P. A. (2024). Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in adolescents, adults, and older adults: A report from the American Dental Association Science and Research Institute, the University of Pittsburgh, and the University of Pennsylvania. The Journal of the American Dental Association, 155(2), 102-117.e9. https://doi.org/10.1016/j.adaj.2023.10.009

Powered by WPeMatico